| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C12H12O9 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Mumefural is a bioactive component of the processed fruit of Prunus mume Sieb. It inhibits platelet aggregation, produces anti-thrombotic effects, and ameliorates cognitive impairment[1][2]. It is supplied as a white to off-white solid (C12H12O9, MW 300.22) at 95.17% purity.
Physical & Chemical Properties
| CAS Number | 222973-44-6 |
|---|---|
| Molecular Formula | C12H12O9 |
| Molecular Weight | 300.22 g/mol |
| Purity | 95.17% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | O=C(CC(C(O)=O)(O)CC(O)=O)OCC1=CC=C(C=O)O1 |
| Target | NF-κB, TLR4, P-selectin, E-selectin, TNF-α |
| Signaling Pathway | Cytoskeleton; NF-κB; Immunology/Inflammation; Apoptosis |
| Solubility | In Vitro: DMSO: 100 mg/mL (333.09 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (333.09 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (8.33 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.5 mg/mL (8.33 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.5 mg/mL (8.33 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vivo
In rats, Mumefural (0.1-10 mg/kg; i.p.; once) shows anti-thrombotic effects[1]. Mumefural (oral; 20-80 mg/kg; daily for 42 days) alleviates cognitive impairment in chronic cerebral hypoperfusion by regulating the septohippocampal cholinergic system and neuroinflammation[2].
| Animal Model | SD rats, FeCl3-induced arterial thrombosis model[1] |
|---|---|
| Dosage | 0.1, 1, or 10 mg/kg |
| Administration | Intraperitoneal injection, 30 min before 35% FeCl3 treatment |
| Result | Significantly improved blood flow by inhibiting occlusion and thrombus formation. Prevented collagen fiber damage in injured vessels and inhibited the expression of the platelet activation-related proteins P-selectin and E-selectin. Significantly reduced the increased inflammatory signal of nuclear factor (NF)-κB, toll-like receptor 4 (TLR4), tumor necrosis factor (TNF)-α, and interleukin (IL)-6 in blood vessels. |
| Animal Model | Male Wistar rats, Chronic cerebral hypoperfusion (CCH) model[2] |
|---|---|
| Dosage | 20, 40, or 80 mg/kg |
| Administration | Oral, once a day for 42 days |
| Result | Significantly improved cognitive impairment. Inhibited cholinergic system dysfunction, attenuated choline acetyltransferase-positive cholinergic neuron loss. Inhibited myelin basic protein degradation and increased the hippocampal expression of synaptic markers and cognition-related proteins. Reduced neuroinflammation, inhibited gliosis, and attenuated the activation of P2X7 receptor, TLR4/MyD88, NLRP3, and NF-κB. |
| Animal Model | SD rats[1] |
|---|---|
| Dosage | 2 or 10 mg/kg |
| Administration | IV or PO (Pharmacokinetic Analysis) |
| Result | Plasma pharmacokinetic parameters of Mumefural in SD rats[1] T1/2 (h) Tmax (h) Cmax (ng/mL) AUC0-t (ng⋅h/mL) F (%) IV (2 mg/kg) 0.14±0.05 0.08±0 1894.54±580.66 564.73±178.35 - PO (2 mg/kg) 0.69±0.69 0.31±0.13 1731.61±290.64 1043.28±202.37 36.95±7.17 AUC(0–t): area under the curve from the time of dosing to infinity; Cmax: maximum concentration; F: bioavailability; T1/2: terminal half-life; Tmax: time of the maximum concentration; SD: standard deviation; F was calculated using the following formula |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
